Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 4
2007 2
2008 1
2009 2
2010 5
2011 8
2012 7
2013 5
2014 13
2015 11
2016 11
2017 6
2018 8
2019 10
2020 13
2021 10
2022 11
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Rhinitis control and medication use in a real-world sample of patients with persistent rhinitis or rhinosinusitis: a community pharmacy study.
Scheire S, Germonpré S, Mehuys E, Van Tongelen I, De Sutter A, Steurbaut S, Van Hees T, Demarche S, Lahousse L, Gevaert P, Boussery K. Scheire S, et al. Among authors: boussery k. J Allergy Clin Immunol Pract. 2024 Apr 25:S2213-2198(24)00416-1. doi: 10.1016/j.jaip.2024.04.031. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38677586
Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.
Grymonprez M, Capiau A, Steurbaut S, Boussery K, Mehuys E, Somers A, Petrovic M, De Backer TL, Lahousse L. Grymonprez M, et al. Among authors: boussery k. Cardiovasc Drugs Ther. 2023 Nov 6. doi: 10.1007/s10557-023-07521-5. Online ahead of print. Cardiovasc Drugs Ther. 2023. PMID: 37930588
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, Steurbaut S, Lahousse L. Grymonprez M, et al. Among authors: boussery k. Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):722-730. doi: 10.1093/ehjcvp/pvad070. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37791408
Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study.
Grymonprez M, Steurbaut S, Capiau A, Vauterin D, Van Vaerenbergh F, Mehuys E, Boussery K, De Backer TL, Lahousse L. Grymonprez M, et al. Among authors: boussery k. Cardiovasc Drugs Ther. 2023 Sep 14. doi: 10.1007/s10557-023-07507-3. Online ahead of print. Cardiovasc Drugs Ther. 2023. PMID: 37707648
108 results